Provention Bio Inc

+0.02 (+0.38%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)256.49M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.73 Million
Adjusted EPS-$0.50
See more estimates
10-Day MA$3.93
50-Day MA$4.16
200-Day MA$5.71
See more pivots

Provention Bio Inc Stock, NASDAQ:PRVB

55 Broad Street, 2nd floor, Red Bank, New Jersey 07701-1902
United States of America
Phone: +1.908.428.9136
Number of Employees: 82


Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohnâ??s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.